Factors Contributing to the Antiviral Effectiveness of Tenofovir

作者: Rachel A. Murphy , Monica A. Valentovic

DOI: 10.1124/JPET.117.243139

关键词:

摘要: Over 1 million people in the United States are living with human immunodeficiency virus (HIV), which may progress to AIDS. The use of antiviral therapy has successfully controlled rate viral growth patients. Antiviral agents improve quality life and reduce potential for spreading HIV; HIV is currently considered a chronic disease provided patients compliant their medications. Tenofovir nucleoside transcriptase inhibitor that prevents replication approved treatment hepatitis B infection. an antiretroviral drug used alone combination other reverse-transcriptase lower load administered as prodrug increase bioavailability. forms tenofovir disoproxil fumarate, 2001, alafenamide, 2016. extensively controlling HIV, it once daily, allowing good compliance. This minireview discusses impact food, age, transporters on absorption clearance. changes dosing needed presence renal impairment, common occurrence progression, will also be discussed. special conditions occurring fixed-combination doses containing reviewed, including cobicistat, cytochrome P450 3A4 inhibitor. short review addresses some newer preparations using niosomes delivery target cells.

参考文章(89)
Tomas Cihlar, Genevieve Laflamme, Adrian S Ray, Jennifer E Vela, Gerald R Rhodes, Leah Tong, Anupma Roy, Michael D Fuller, Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antiviral Therapy. ,vol. 12, pp. 267- 272 ,(2007)
Klotman Pe, Schwartz Ej, Pathogenesis of human immunodeficiency virus (HIV)-associated nephropathy. Seminars in Nephrology. ,vol. 18, pp. 436- 445 ,(1998)
Joseph W. Polli, Jeanne L. Jarrett, Scott D. Studenberg, Joan E. Humphreys, Steven W. Dennis, Kenneth R. Brouwer, Joseph L. Woolley, Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharmaceutical Research. ,vol. 16, pp. 1206- 1212 ,(1999) , 10.1023/A:1018941328702
Hélène CF Côté, Alex B Magil, Marianne Harris, Brian J Scarth, Izabelle Gadawski, Nancy Wang, Eugenia Yu, Benita Yip, Nadia Zalunardo, Ron Werb, Robert Hogg, P Richard Harrigan, Julio S Montaner, None, Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antiviral Therapy. ,vol. 11, pp. 79- 86 ,(2006)
Pedro Rodríguez Quesada, Laura López Esteban, Jimena Ramón García, Rocío Vázquez Sánchez, Teresa Molina García, Gabriel Gaspar Alonso-Vega, Javier Sánchez-Rubio Ferrández, Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. International Journal of Clinical Pharmacy. ,vol. 37, pp. 865- 872 ,(2015) , 10.1007/S11096-015-0132-1
Brian P Kearney, John F Flaherty, Jaymin Shah, Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical Pharmacokinectics. ,vol. 43, pp. 595- 612 ,(2004) , 10.2165/00003088-200443090-00003
Jeng‐Pyng Shaw, Cathy M. Sueoka, Reza Oliyai, William A. Lee, Murty N. Arimilli, Choung U. Kim, Kenneth C. Cundy, Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharmaceutical Research. ,vol. 14, pp. 1824- 1829 ,(1997) , 10.1023/A:1012108719462
Jan Van Gelder, Pieter Annaert, Lieve Naesens, Erik De Clercq, Guy Van den Mooter, Renaat Kinget, Patrick Augustijns, Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study. Pharmaceutical Research. ,vol. 16, pp. 1035- 1040 ,(1999) , 10.1023/A:1018931631912
Elizabeth M. Sherman, Marylee V. Worley, Nathan R. Unger, Timothy P. Gauthier, Jason J. Schafer, Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection Clinical Therapeutics. ,vol. 37, pp. 1876- 1893 ,(2015) , 10.1016/J.CLINTHERA.2015.07.022
BM Best, S Burchett, H Li, A Stek, C Hu, J Wang, E Hawkins, M Byroads, DH Watts, E Smith, CV Fletcher, EV Capparelli, M Mirochnick, , Pharmacokinetics of tenofovir during pregnancy and postpartum Hiv Medicine. ,vol. 16, pp. 502- 511 ,(2015) , 10.1111/HIV.12252